Phil Kantoff's guest appearances

Phil Kantoff

Empowered Patient Podcast

The Uromigos

HealthBiz with David E. Williams

Mark Allen

David Katz

Rosalind Picard

David Solomon

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Robin Zander

OwlTail

Convergent Therapeutics is a clinical stage startup company bringing a new approach to the deployment of radiopharmaceuticals to treat and possibly even cure certain cancers, starting with the prostate.Support the showHost David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.

Convergent Therapeutics is a clinical stage startup company bringing a new approach to the deployment of radiopharmaceuticals to treat and possibly even cure certain cancers, starting with the prostate.<a href="https://www.buzzsprout.com/1367974/support" rel="payment nofollow" target="_blank">Support the show</a>Host <a href="https://www.linkedin.com/in/davideugenewilliams/" rel="nofollow" target="_blank">David E. Williams</a> is president of healthcare strategy consulting firm <a href="https://www.healthbusinessgroup.com/" rel="nofollow" target="_blank">Health Business Group</a>. Produced by <a href="https://www.linkedin.com/in/dafna-williams-53aaa7199/" rel="nofollow" target="_blank">Dafna Williams</a>.

Interview with Convergent Therapeutics CEO Dr. Phil Kantoff

Alex Brown

Dr. Phil Kantoff is the CEO and Co-Founder and Alex Brown is the COO of Convergent Therapeutics which is developing the next generation of targeted therapies to treat cancer. Drawing on insights from developments in radiopharmaceuticals, Convergent focuses on radioantibodies that are radioisotopes attached to antibodies directed to treat prostate cancer. Phil explains, "Antibodies will recognize surface molecules on cancer cells and they can be linked to radioisotopes. We are focused on an isotope known as Actinium-225, which is an important radioisotope because it's different than isotopes that have been previously used, it's an alpha-emitting radiopharmaceutical. Alpha particles are much larger, they're much more powerful, and they travel a shorter distance. You can deliver a very powerful, very targeted therapy to cancer." "We have clinical trials that are taking place right now that are showing remarkable activity using the combination of the directed antibody against prostate cancer cells, specifically prostate-specific membrane antigen coupled to this isotope, Actinium-225." Alex continues, "Our radioantibodies, which is what we're talking about here, are novel enough that there are few if any, examples of marketed products out there. It's a field that's emerging, so aside from having the experience in antibody development and commercialization, some of this is new to our team as well as to others." @ConvergentRx @DrPhilKantoff #ProstateCancer #Radiopharmaceuticals #PSMA #Radioantibody #RadioLingandTherapy #Oncology #Biotechnology ConvergentRx.com Download the transcript here

Dr. Phil Kantoff is the CEO and Co-Founder and Alex Brown is the COO of Convergent Therapeutics which is developing the next generation of targeted therapies to treat cancer. Drawing on insights from developments in radiopharmaceuticals, Convergent focuses on radioantibodies that are radioisotopes attached to antibodies directed to treat prostate cancer. Phil explains, "Antibodies will recognize surface molecules on cancer cells and they can be linked to radioisotopes. We are focused on an isotope known as Actinium-225, which is an important radioisotope because it's different than isotopes that have been previously used, it's an alpha-emitting radiopharmaceutical. Alpha particles are much larger, they're much more powerful, and they travel a shorter distance. You can deliver a very powerful, very targeted therapy to cancer." "We have clinical trials that are taking place right now that are showing remarkable activity using the combination of the directed antibody against prostate cancer cells, specifically prostate-specific membrane antigen coupled to this isotope, Actinium-225." Alex continues, "Our radioantibodies, which is what we're talking about here, are novel enough that there are few if any, examples of marketed products out there. It's a field that's emerging, so aside from having the experience in antibody development and commercialization, some of this is new to our team as well as to others." @ConvergentRx @DrPhilKantoff #ProstateCancer #Radiopharmaceuticals #PSMA #Radioantibody #RadioLingandTherapy #Oncology #Biotechnology <a href="http://ConvergentRx.com" rel="noopener nofollow" target="_blank">ConvergentRx.com</a> <a href="http://empoweredpatientradio.com/radiopharmaceutical-technology-creates-novel-radioantibodies-to-treat-prostate-cancer-with-dr-phil-kantoff-and-alex-brown-convergent-therapeutics-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Radiopharmaceutical Technology Creates Novel Radioantibodies to Treat Prostate Cancer with Dr. Phil Kantoff and Alex Brown Convergent Therapeutics

Phil discusses his career progression and prostate cancer. 

Phil discusses his career progression and prostate cancer.

Episode 129: Phil Kantoff - The Uromigos Legends in GU Cancer series 